How big is Surrozen, Inc.?

As of Jun 18, Surrozen, Inc. has a market capitalization of 78.95 million, with net sales of 11.64 million and a net profit of -81.70 million over the latest four quarters. Shareholder's funds are reported at -21.38 million, and total assets amount to 48.47 million.

As of Jun 18, Surrozen, Inc. has a market capitalization of 78.95 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 11.64 million, while the sum of net profit for the same period is -81.70 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -21.38 million, and total assets amount to 48.47 million.

What does Surrozen, Inc. do?

Surrozen, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $1 million and a net loss of $27 million. It has a market cap of $78.95 million and key metrics include a P/E ratio of 6.00 and a return on equity of 214.31%.

Overview: <BR>Surrozen, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 78.95 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 6.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -17.70 <BR>Return on Equity: 214.31% <BR>Price to Book: 13.91<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Surrozen, Inc.?

Is Surrozen, Inc. overvalued or undervalued?

As of November 6, 2024, Surrozen, Inc. is classified as risky due to its low P/E ratio of 6 and EV to EBITDA ratio of 1.12, despite a high ROE of 214.31% and a strong one-year return of 49.56%, indicating potential overvaluation concerns relative to its peers.

As of 6 November 2024, Surrozen, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued based on its current valuation metrics. The P/E ratio stands at 6, which is significantly lower than the industry average, while the EV to EBITDA ratio is 1.12, indicating potential inefficiencies in earnings relative to enterprise value. Additionally, the PEG ratio is exceptionally low at 0.05, suggesting that the stock may be undervalued in terms of growth expectations, but this is offset by the overall risk profile.<BR><BR>In comparison to its peers, Surrozen, Inc. has a P/E of 7.84, which is higher than Elutia, Inc. at -2.83 and GeoVax Labs, Inc. at -0.71, both of which are also classified as risky. The company’s ROE is notably high at 214.31%, indicating strong profitability relative to equity, but this does not mitigate the overall valuation concerns. Over the past year, Surrozen, Inc. has returned 49.56%, significantly outperforming the S&P 500's 17.14%, which may reflect short-term investor sentiment despite the underlying valuation risks.

Is Surrozen, Inc. technically bullish or bearish?

As of September 9, 2025, Surrozen, Inc. shows a mildly bullish technical trend with strong weekly indicators, despite some bearish signals, having outperformed the S&P 500 over the past year but underperformed year-to-date.

As of 9 September 2025, the technical trend for Surrozen, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The Bollinger Bands also reflect a bullish stance on the weekly and a mildly bullish stance on the monthly. Daily moving averages are bullish, supporting the overall positive trend. However, the KST shows a mildly bearish monthly signal, and Dow Theory indicates a mildly bearish weekly outlook, which tempers the bullish sentiment. <BR><BR>In terms of performance, Surrozen has outperformed the S&P 500 over the past year with a return of 49.56% compared to the S&P 500's 17.14%, but it has underperformed year-to-date with a return of -16.52% against the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators and positive longer-term performance.